The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by debilitating motor and non-motor symptoms. Its etiology is multifactorial, with no single definitive cause identified, although aging is a significant risk factor. Additional risks include genetic predispo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Engineering Microbiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667370325000360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849254259746406400 |
|---|---|
| author | Shabnam Santos Ivonne Salinas Nicolás Almeida Andrés Caicedo |
| author_facet | Shabnam Santos Ivonne Salinas Nicolás Almeida Andrés Caicedo |
| author_sort | Shabnam Santos |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by debilitating motor and non-motor symptoms. Its etiology is multifactorial, with no single definitive cause identified, although aging is a significant risk factor. Additional risks include genetic predisposition, family history, and environmental factors such as pesticide exposure and Helicobacter pylori infection. Dysbiosis of the gut microbiota, and in particular bacterial imbalances, has been implicated in the disruption of the gut-brain axis, contributing to both systemic and neuroinflammation. Environmental factors such as antibiotic exposure and toxins can precipitate microbial dysregulation, potentially accelerating PD progression. Understanding the mechanisms of the gut-brain axis and identifying strategies to preserve a healthy microbiome are essential for developing novel therapeutic approaches. This review synthesizes current therapeutic strategies and ongoing research focused on restoring gut-brain balance to combat PD. These approaches include fecal microbiota transplantation, dietary interventions, and probiotic therapies, all of which show promise in mitigating both motor and non-motor symptoms. Furthermore, we emphasize the urgent need for continued research into probiotics and innovative therapeutic approaches for gut-brain axis modulation, presenting novel opportunities for effective PD management. |
| format | Article |
| id | doaj-art-cdb99c87719b4ac8b2ef4b7baab80bc4 |
| institution | Kabale University |
| issn | 2667-3703 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Engineering Microbiology |
| spelling | doaj-art-cdb99c87719b4ac8b2ef4b7baab80bc42025-08-20T03:56:04ZengElsevierEngineering Microbiology2667-37032025-09-015310022210.1016/j.engmic.2025.100222The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunitiesShabnam Santos0Ivonne Salinas1Nicolás Almeida2Andrés Caicedo3Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, Escuela de Medicina, Quito, Ecuador; Universidad San Francisco de Quito USFQ, Instituto de Investigaciones en Biomedicina, Quito, Ecuador; Mito-Act Research Consortium, Quito, EcuadorUniversidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, Escuela de Medicina, Quito, Ecuador; Universidad San Francisco de Quito USFQ, Instituto de Investigaciones en Biomedicina, Quito, Ecuador; Mito-Act Research Consortium, Quito, EcuadorUniversidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, Escuela de Medicina, Quito, Ecuador; Universidad San Francisco de Quito USFQ, Instituto de Investigaciones en Biomedicina, Quito, Ecuador; Mito-Act Research Consortium, Quito, EcuadorUniversidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, Escuela de Medicina, Quito, Ecuador; Universidad San Francisco de Quito USFQ, Instituto de Investigaciones en Biomedicina, Quito, Ecuador; Mito-Act Research Consortium, Quito, Ecuador; Universidad San Francisco de Quito USFQ, USFQ Space Front, Quito, Ecuador; Corresponding author.Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by debilitating motor and non-motor symptoms. Its etiology is multifactorial, with no single definitive cause identified, although aging is a significant risk factor. Additional risks include genetic predisposition, family history, and environmental factors such as pesticide exposure and Helicobacter pylori infection. Dysbiosis of the gut microbiota, and in particular bacterial imbalances, has been implicated in the disruption of the gut-brain axis, contributing to both systemic and neuroinflammation. Environmental factors such as antibiotic exposure and toxins can precipitate microbial dysregulation, potentially accelerating PD progression. Understanding the mechanisms of the gut-brain axis and identifying strategies to preserve a healthy microbiome are essential for developing novel therapeutic approaches. This review synthesizes current therapeutic strategies and ongoing research focused on restoring gut-brain balance to combat PD. These approaches include fecal microbiota transplantation, dietary interventions, and probiotic therapies, all of which show promise in mitigating both motor and non-motor symptoms. Furthermore, we emphasize the urgent need for continued research into probiotics and innovative therapeutic approaches for gut-brain axis modulation, presenting novel opportunities for effective PD management.http://www.sciencedirect.com/science/article/pii/S2667370325000360Gut-brain axisMicrobiota dysbiosisParkinson’s diseaseProbiotic therapyNeuroinflammation |
| spellingShingle | Shabnam Santos Ivonne Salinas Nicolás Almeida Andrés Caicedo The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities Engineering Microbiology Gut-brain axis Microbiota dysbiosis Parkinson’s disease Probiotic therapy Neuroinflammation |
| title | The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities |
| title_full | The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities |
| title_fullStr | The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities |
| title_full_unstemmed | The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities |
| title_short | The role of microbiota dysbiosis in Parkinson’s disease: Pathophysiology and therapeutic opportunities |
| title_sort | role of microbiota dysbiosis in parkinson s disease pathophysiology and therapeutic opportunities |
| topic | Gut-brain axis Microbiota dysbiosis Parkinson’s disease Probiotic therapy Neuroinflammation |
| url | http://www.sciencedirect.com/science/article/pii/S2667370325000360 |
| work_keys_str_mv | AT shabnamsantos theroleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT ivonnesalinas theroleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT nicolasalmeida theroleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT andrescaicedo theroleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT shabnamsantos roleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT ivonnesalinas roleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT nicolasalmeida roleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities AT andrescaicedo roleofmicrobiotadysbiosisinparkinsonsdiseasepathophysiologyandtherapeuticopportunities |